Myovant Sciences Shares Outstanding 2017-2022 | MYOV
Myovant Sciences shares outstanding from 2017 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Myovant Sciences Annual Shares Outstanding
(Millions of Shares) |
| 2022 |
93 |
| 2021 |
90 |
| 2020 |
86 |
| 2019 |
67 |
| 2018 |
60 |
| 2017 |
49 |
| 2016 |
37 |
Myovant Sciences Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-06-30 |
95 |
| 2022-03-31 |
93 |
| 2021-12-31 |
93 |
| 2021-09-30 |
92 |
| 2021-06-30 |
92 |
| 2021-03-31 |
90 |
| 2020-12-31 |
90 |
| 2020-09-30 |
90 |
| 2020-06-30 |
89 |
| 2020-03-31 |
86 |
| 2019-12-31 |
89 |
| 2019-09-30 |
89 |
| 2019-06-30 |
76 |
| 2019-03-31 |
67 |
| 2018-12-31 |
68 |
| 2018-09-30 |
67 |
| 2018-06-30 |
63 |
| 2018-03-31 |
60 |
| 2017-12-31 |
60 |
| 2017-09-30 |
59 |
| 2017-06-30 |
59 |
| 2017-03-31 |
49 |
| 2016-12-31 |
54 |
| 2016-09-30 |
43 |
| 2016-06-30 |
41 |
| 2016-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.693B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
